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Abstract
Problem: We investigated if the PROGINS mutation increases the risk of hepatitis
E virus (HEV) infection in liver transplant recipients. PROGINS was analyzed
through KASP assay; HEV serologies assessed via enzyme‐linked immunosorbent
assay and multiplex cytokine assays were evaluated in plasma with the Procarta-
Plex human immunoassay. Seventy liver transplant recipients were evaluated, of
which 23 (33%) were HEV immunoglobuln G (IgG)‐positive (HEV+). The frequency
of PROGINS in the HEV+ group was 34%, compared with 14% in those that were
HEV IgG negative (HEV−). Cytokine measurements in a sub‐set of samples from
HEV+/PROGINS+ individuals showed decreased plasma levels of monokine
induced by gamma interferon, a proliferation‐inducing ligand, and stem cell factor,
as well as increased levels of eotaxin‐3 and interleukin‐31 compared with those
HEV−/PROGINS− samples. Our findings suggest an association between the
PROGINS mutation and seropositivity for HEV in liver transplant recipients with
consequent distorted cytokine levels.
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1 | INTRODUCTION
Infection with the hepatitis E virus (HEV) can cause acute hepatitis in
immunocompetent hosts as well as liver failure in pregnant women, and
can lead to chronic infection or acute reactivation, the latter as case
reports, in solid organ transplant recipients.1‐3 Overall, the under-
standing of mechanisms and host factors that affect prevalence or
predispose to HEV infection in individuals with immune‐suppression or
undergoing pregnancy is limited.4 Moreover, whether risk factors that
predispose to viral infection in these two conditions are interrelated
remains undefined. Interestingly, a study by Bose et al5 described a
mutation in the progesterone receptor (PR) named PROGINS to
be associated with acute viral hepatitis and fulminant hepatic failure
secondary to HEV in pregnant women. During pregnancy, progesterone
exerts an important effect on peripheral lymphocytes expressing PR to
modulate uterine immunity. The PROGINS mutation, which depending
on the specific ethnicity can affect 2% to 14% of the population, consists
of two single nucleotide polymorphism (SNP) with a G‐intron insert, and
past studies have demonstrated the mutation to affect the functionality
of the PR.6,7 It is theorized that progesterone could have a differential
effect on peripheral lymphocytes expressing PR in individuals with the
mutation, therefore predisposing them to HEV infection.8 Our team
recently showed that the PROGINS mutation is expressed with a higher
frequency in individuals with human immunodeficiency virus (HIV) who
are seropositive for HEV and that the mutation conferred alterations in
peripheral immune markers as well as a decreased T‐cell response.9
That study showed for the first time that the mutation in the PR could
confer high risk for HEV in a nonpregnant immune‐suppressed cohort.
Since HEV can reactivate or lead to chronic hepatitis in solid‐organ
transplant recipients more frequently than in other populations,
we thought to determine the presence of PROGINS in liver transplant
recipients and its association to HEV infection.
2 | MATERIALS AND METHODS
2.1 | Samples
We evaluated plasma samples from 70 individuals who received a liver
transplantation and analyzed them for the presence of PROGINS.
Samples were collected between 2000 and 2015 and kept at −80°C.
Median age at collection was 58 years (interquartile range [IQR],
41‐65) and 27% were females. A group of 187 healthy samples pre-
viously described were used as controls.9 We obtained approval for
our study by the Medical Ethical Review Board of the Erasmus Medical
Center (reference number MEC‐ 2011‐438).
2.2 | Hepatitis E virus and single nucleotide
polymorphism determination
For detection of HEV specific immunoglobulin M and immunoglobulin
G (IgG) we used the commercially available enzyme‐linked im-
munosorbent assay (ELISA) test (Wantai, China) according to the
manufacturer's instructions. For genotyping, competitive allele‐specific
polymerase chain reaction assays (KASP; LGC genomics, Huddleston,
UK) were employed. The PROGINS allele was defined by the exon
4 missense SNP rs1042838, Val660Leu, as previously described.10
Plasma samples stored at −80°C were used for DNA extraction and
genotyping procedures which were carried out at LGC genomics using
≥5 ng of genomic DNA.11
2.3 | Cytokine assessment
For the assessment of cytokines/chemokines and other plasma pro-
teins, we performed multi‐analyte profiling using the ProcartaPlex
human immunoassay (Affymetrix, eBioscience, Austria). The panel
measured APRIL, BAFF, eotaxin‐3 (CCL26), FGF‐2, G‐CSF, GRO‐α,
interleukin‐1α (IL‐1α), IL‐1β, IL‐21, IL‐22, IL‐23, IL‐3, monokine induced
by gamma interferon (MIG) (CXCL9), stem cell factor (SCF), tumor
necrosis factor‐α, IL‐8, IL‐31, LIF, MIP‐3α, TRAIL, TWEAK, and vascular
endothelial growth factor‐A. The assay was conducted according to
the manufacturer's instructions, identical to the procedures used in
our previous studies.12 All samples were analyzed in one run. Statis-
tical analyses: During statistical analyses, baseline characteristics were
compared between HEV IgG positive and negative patients expressing
PROGINS mutation or wild type PR. In general, quantitative compar-
isons were performed using the parametric the Student t test
(for normally distributed values) and the nonparametric Wilcoxon
test or Mann‐Whitney tests (for values that did not show a normal
distribution). A P < .05 was considered statistically significant.
3 | RESULTS
Of the 70 liver transplant recipients, 47 (67.1%) were HEV IgG‐
negative (HEV−) and 23 (32.8%) HEV IgG‐positive (HEV+) as as-
sessed by ELISA. We found the frequency of PROGINS in HEV+ to
be 34.7% (N:8), compared with 14.7% (N:7) in those that were
HEV− (RR, 2.2; confidence interval, 0.9‐5.5; P = .01; Figure 1). Inter-
estingly, the HEV‐ liver transplant recipient cohort showed a similar
frequency of PROGINS as that of our control group (14% each),
suggesting that indeed the mutation could confer a risk factor for an
altered immune response towards the virus upon exposure. Demo-
graphics between both groups (HEV− and HEV+) were similar, with
median age of both groups at 57 years (IQR, 47‐62 and 41‐64,
respectively) and a similar proportion of males (70% and 68%,
respectively), suggesting that neither factor played a role in this
setting. Almost half of the HEV+ patients (10/23) became ser-
opositive following liver transplantation (median time 3 years; IQR,
2‐7). In this group, 50% (N:5) had the presence of the PROGINS
mutation, further strengthening the concept of an association be-
tween HEV‐seropositivity and the PROGINS mutation in liver
transplant recipients. The specific route of HEV transmission in this
cohort could not be established.
F IGURE 1 Pie charts showing frequency of PROGINS as a percentage in (A) healthy controls (N:187); (B) liver transplant recipients
HEV− (N:47), and (C) liver transplant recipients HEV+ (N:23). Dark color indicates presence of PROGINS mutation and gray color indicates wild‐
type progesterone receptor. P value compares difference in PROGINS frequency between liver transplant recipients HEV− and HEV+. HEV,
hepatitis E virus
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Next, we performed multi‐analyte profiling of 22 immune
markers in plasma in a subgroup of HEV+ and HEV− liver transplant
recipients who expressed the PROGINS mutation and a group of
HEV− recipients without the PROGINS mutation (N:7 in each
group). We found increased levels of eotaxin‐3 (CCL26) and IL‐31,
both predominantly implicated in Th2 dominated responses, and
reduced plasma levels of MIG; CXCL9, APRIL, and SCF in the
HEV+/PROGINS+ individuals when compared with HEV− liver
transplant recipients regardless of mutation status (Figure 2). MIG,
APRIL, and SCF are chemotactic and play a role in recruiting cells
during inflammatory responses, or directly affect the function of
T and B cells.13 From these proteins only SCF (P = .01), and APRIL
(P = .02) showed statistical significance, while IL‐31 showed a
P = .05. In our cohort, only three individuals developed chronic HEV
infection with one of them expressing the PROGINS mutation. With
such a low number of subjects we cannot hypothesize on the role of
PROGINS in the progression towards HEV chronicity.
4 | DISCUSSION
Our group recently described that the presence of the PROGINS
mutation induced an impaired immune response in HIV‐positive in-
dividuals and was associated with HEV‐seropositivity in such patients.9
We then hypothesized that a “dual immune hit” represented by
the mutation coupled with that induced by HIV could abrogate the
response towards HEV exposure. In the current study, we found that a
similar effect could occur in liver transplant recipients.
HEV+ patients with PROGINS mutation expressed altered plas-
ma levels of multiple immune markers when compared with those
without the mutation. The observed alterations in plasma levels in
HEV+ patients with PROGINS mutation are suggestive of weaker
antiviral immune responses in the group since the levels of Th2‐
associated proteins IL‐31 and eotaxin‐3 were enhanced, while the
proinflammatory markers MIG, APRIL reduced.13,14 The high fre-
quency of the PROGINS mutation in the HEV+ patients combined
with altered plasma cytokine profile warrant further detailed studies
on the concept of an impaired immune response secondary to the
presence of the mutation. However, caution should be used when
interpreting these findings as they represent a one‐time cross‐
sectional measurement in a small sub‐group of individuals. Moreover,
a recent study performed entirely in an HIV‐population suggests an
inverse correlation between PROGINS and HEV infection.15 In ad-
dition, it is possible that cytokine levels are secondary to HEV ser-
ostatus, and that the cytokines are affected by immunosuppressive
drugs administered to prevent graft rejection. Finally, only two of the
proteins showed statistical significance, although the trend among
the others was evident. With our low number of samples and
F IGURE 2 Plasma levels of IL‐31, Eotaxin 3, SCF, MIG, and APRIL in 21 individuals (seven HEV+/SNP+, seven HEV−/SNP+, and seven HEV
−/SNP−), measured with multiplex ELISA. Y‐axis represents levels in pg/mL; X‐axis represents the different groups. P values represent
comparison between HEV−/SNP− and HEV+/SNP+. APRIL, a proliferation‐inducing ligand; ELISA, enzyme‐linked immunosorbent assay; HEV,
hepatitis E virus; IL, interleukin; MIG, monokine induced by gamma interferon; SCF, stem cell factor; SNP, single‐nucleotide polymorphism
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common variations of cytokines in blood, these specific findings
should be addressed in a larger cohort before solid conclusions
are drawn. In summary, our results show an association with the
PROGINS mutation and HEV seroprevalence in liver transplant
recipients. A larger validation study, as well as a study involving other
solid organ transplant populations will be necessary to further un-
derstand the role of PROGINS in this setting. Our findings albeit from
a small cohort, suggest an association between seropositivity for HEV
and the PROGINS mutation in liver transplant recipients. This asso-
ciation correlated with alternations in peripheral cytokine levels,
further strengthening the concept of an immune‐related effect.
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